Ginkgo Bioworks Holdings, Inc. (DNA)
| Market Cap | 672.73M -5.0% |
| Revenue (ttm) | 132.42M -37.0% |
| Net Income | -290.80M |
| EPS | -4.96 |
| Shares Out | 67.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,156,002 |
| Open | 9.61 |
| Previous Close | 9.71 |
| Day's Range | 9.43 - 9.99 |
| 52-Week Range | 5.37 - 18.22 |
| Beta | 1.79 |
| Analysts | Sell |
| Price Target | 8.00 (-19.92%) |
| Est. Earnings | Nov 5, 2026 |
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engi... [Read more]
Financial Performance
In 2025, Ginkgo Bioworks Holdings's revenue was $170.16 million, a decrease of -25.06% compared to the previous year's $227.04 million. Losses were -$312.76 million, -42.83% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for DNA stock is "Sell." The 12-month stock price target is $8.0, which is a decrease of -19.92% from the latest price.
News
Ginkgo Bioworks price target raised to $11 from $9 at TD Cowen
TD Cowen raised the firm’s price target on Ginkgo Bioworks (DNA) to $11 from $9 and keeps a Hold rating on the shares. The firm adjusted targets in the life…
Ginkgo Bioworks to provide autonomous lab access to NSF X-Labs researchers
Ginkgo Bioworks (DNA) announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation’s X-Labs program. Ginkgo’s support was announced t...
Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation's X-Labs prog...
Ginkgo Bioworks announces integration of Araceli Endeavor
Araceli Biosciences and Ginkgo Bioworks (DNA) announced the integration of Araceli’s Endeavor high-content imaging instrument into Nebula, Ginkgo’s autonomous lab in Boston. The Endeavor brings cellul...
Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
The Endeavor® adds the fastest high-content cellular data generation to Ginkgo's around-the-clock research PORTLAND, Ore. and BOSTON, Oct. 8, 2026 /PRNewswire/ -- Araceli Biosciences and Ginkgo Biowo...
Ginkgo Bioworks, Apheris announce kick off of Antibody Developability Consortium
Ginkgo Datapoints (DNA) and Apheris announced that the Antibody Developability Consortium has kicked off with its founding members. The Consortium is a new industry collaboration designed to help phar...
Ginkgo Bioworks announces partnership with Lilly TuneLab
Ginkgo Bioworks (DNA) announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company…
Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platf...
Ginkgo Bioworks awarded up to $17.5M subcontract under ARPA-H GIVE program
Ginkgo Bioworks (DNA) has been awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Health’s Genetic Medicines and Individualized Manufacturing for Everyone program. ...
Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it has been awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Health's (ARPA-H) Genetic M...
Ginkgo Bioworks downgraded to Hold from Buy at TD Cowen
TD Cowen analyst Brendan Smith downgraded Ginkgo Bioworks (DNA) to Hold from Buy with a price target of $9, down from $12. The company reported another sales miss in Q2,…
Ginkgo Bioworks Holdings Earnings Call Transcript: Q2 2026
Q2 revenue fell 48% YoY, while H1 cash burn declined 3% to $93M; 2026 cash-burn guidance remains $125M–$150M. Nebula expansion, university lab awards, and ADME-One launch advance the autonomous-lab strategy.
Ginkgo Bioworks Holdings Earnings release: Q2 2026
Ginkgo Bioworks Holdings released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Ginkgo Bioworks Holdings Slides: Q2 2026
Ginkgo Bioworks Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Ginkgo Bioworks Holdings Quarterly report: Q2 2026
Ginkgo Bioworks Holdings has published its Q2 2026 quarterly earnings report on August 5, 2026.
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to mak...
Ginkgo Bioworks reaffirms 2026 expected total cash burn of ($150M)-($125M)
16:38 EDT Ginkgo Bioworks (DNA) reaffirms 2026 expected total cash burn of ($150M)-($125M)
Ginkgo Bioworks Holdings Earnings Call Transcript: Q1 2026
Revenue and cash burn declined year-over-year as restructuring and the biosecurity spin-off took effect. The company is investing heavily in autonomous labs, with Nebula now exceeding 100 RACs and new partnerships expanding cloud-based lab services. Strong cash reserves support continued innovation.
Ginkgo Bioworks Holdings Earnings release: Q1 2026
Ginkgo Bioworks Holdings released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Ginkgo Bioworks Holdings Quarterly report: Q1 2026
Ginkgo Bioworks Holdings has published its Q1 2026 quarterly earnings report on May 7, 2026.
Ginkgo Bioworks Holdings Slides: Q1 2026
Ginkgo Bioworks Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "G...
Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation
Presentation and Q&A session scheduled for post-market on Thursday, May 7, 2026 BOSTON, April 30, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plan...
Ginkgo Bioworks Holdings Proxy statement: Proxy filing
Ginkgo Bioworks Holdings filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Ginkgo Bioworks Holdings Proxy statement: Proxy filing
Ginkgo Bioworks Holdings filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.